drugset

drugset / Trial / NCT06098027

Study of [14C]CS0159 in China Healthy Subjects

NCT06098027 ↗

Phase 1 Completed 6 enrolled Cascade Pharmaceuticals, Inc

NaSingle-groupOpen-labelOther

Summary

Study of \[14C\]CS0159 in China Healthy Subjects.

Timeline

Start: 2023-10-23
Primary completion: 2023-11-02
Completion: 2023-11-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CS0159	Unknown	4 mg	Oral

Indications